Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Return on Equity (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Return on Equity for 5 consecutive years, with 24.35% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity rose 2813.0% to 24.35% in Q3 2025 year-over-year; TTM through Sep 2025 was 24.35%, a 2813.0% increase, with the full-year FY2024 number at 1.85%, down 111.0% from a year prior.
  • Return on Equity was 24.35% for Q3 2025 at Lyra Therapeutics, up from 14.14% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 24.35% in Q3 2025 to a low of 14.14% in Q2 2025.
  • A 5-year average of 1.25% and a median of 0.82% in 2023 define the central range for Return on Equity.
  • Biggest YoY gain for Return on Equity was 2813bps in 2025; the steepest drop was -1227bps in 2025.
  • Lyra Therapeutics' Return on Equity stood at 1.07% in 2021, then soared by 40bps to 0.64% in 2022, then decreased by -14bps to 0.72% in 2023, then tumbled by -704bps to 5.8% in 2024, then surged by 520bps to 24.35% in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Return on Equity are 24.35% (Q3 2025), 14.14% (Q2 2025), and 10.28% (Q1 2025).